Insulet(PODD)
Focus: Insulet is a public medical device company specializing in insulin pump systems, primarily the Omnipod platform for diabetes management. The company is a mid-cap player with $1.7B in FY2025 revenue and 201-500 employees headquartered in Acton, MA.
Profile data last refreshed 4h ago · AI intelligence enriched 1mo ago
Funding Stage
PUBLIC
Employees
201-500
Open Jobs
164+14 this month
Growing — net +14 jobs in 30d
203 jobs added vs 189 removed. Steady team buildout.
Should You Work at Insulet?
AI assessmentInsulet offers stable growth, strong commercial momentum, and visa sponsorship appeal, but suits device-commercial and engineering talent more than drug development scientists.
Why Work Here
- Strong revenue growth trajectory ($1.3B to $1.7B YoY) with profitability swing to $206M net income in FY2025, signaling operational momentum and job security.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$1.7B
Pipeline & Clinical Trials
Omnipod 5
DiabetesClinical Trials (1)
NCT07039942French Prospective Multicentric Study in Real World
N/AHelp build intelligence for Insulet
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.